-
公开(公告)号：US20240263232A1
公开(公告)日：2024-08-08
申请号：US18420361
申请日：2024-01-23
Applicant: BioNTech SE
Inventor： Ugur SAHIN , Martin SUCHAN , Barbara SCHRÖRS , Martin LÖWER , Petra OEHM
IPC: C12Q1/6876 , C12Q1/686
CPC classification number: C12Q1/6876 , C12Q1/686 , C12Q2600/156
Abstract: This invention relates to methods for screening for a genotype for loss of antigen presentation via MHC class I in a subject and/or respectively detecting a subject's increased risk of resistance against immunotherapy such as against vaccination.
-
公开(公告)号：US20240109972A1
公开(公告)日：2024-04-04
申请号：US18038818
申请日：2021-12-07
Applicant: Genmab A/S , BioNTech SE
Inventor： Ugur SAHIN , Alexander MUIK , Ulf FORSSMANN , Maria JURE-KUNKEL , Manish GUPTA , Tahamtan AHMADI , Kathy AMIRI , Gaurav BAJAJ
IPC: C07K16/28 , A61K31/337 , A61K45/06 , A61P35/00
CPC classification number: C07K16/2878 , A61K31/337 , A61K45/06 , A61P35/00 , C07K16/2827 , A61K2039/505
Abstract: The present invention provides combination therapy to reduce or prevent progression of a tumor or treating cancer in a subject. The combination therapy comprises administration of a binding agent that binds to human CD137 and to human PD-L1; and a taxane chemotherapeutic agent.
-
公开(公告)号：US20230117803A1
公开(公告)日：2023-04-20
申请号：US17759906
申请日：2021-02-02
Applicant: BIONTECH SE
Inventor： Ugur SAHIN , Alexander MUIK , Lena KRANZ , Mathias VORMEHR
Abstract: The present disclosure relates to methods and compositions for inducing an immune response in a subject comprising providing to the subject a peptide or protein vaccine and a binding agent, such as a bispecific antibody, binding to PD-L1 and CD137, such as human PD-L1 and human CD137, e.g., by co-administering to the subject a peptide or protein used for vaccination or a polynucleotide, in particular RNA, encoding a peptide or protein used for vaccination, and a binding agent binding to PD-L1 and CD137 or a polynucleotide, in particular RNA, encoding a binding agent binding to PD-L1 and CD137. The present disclosure further relates to medical preparations useful in the methods disclosed herein.
-
公开(公告)号：US20230114808A1
公开(公告)日：2023-04-13
申请号：US17310773
申请日：2020-03-11
Applicant: BioNTech SE , TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Gemein-N
Inventor： David WEBER , Carina WALTER , Diana BAREA ROLDAN , Ruprecht KUNER , Elif DIKEN , Martin SUCHAN , Stefania GANGI MAURICI , Ugur SAHIN
Abstract: Disclosed herein are compositions, uses, and methods for treatment of prostate cancers. In one aspect, disclosed herein is a composition or medical preparation comprising at least one RNA, wherein the at least one RNA encodes the following amino acid sequences: (i) an amino acid sequence comprising Kallikrein-2 (KLK2), an immunogenic variant thereof, or an immunogenic fragment of the KLK2 or the immunogenic variant thereof; (ii) an amino acid sequence comprising Prostate Specific Antigen (PSA), an immunogenic variant thereof, or an immunogenic fragment of the PSA or the immunogenic variant thereof; (iii) an amino acid sequence comprising Prostatic Acid Phosphatase (PAP), an immunogenic variant thereof, or an immunogenic fragment of the PAP or the immunogenic variant thereof; (iv) an amino acid sequence comprising Homeobox B13 (HOXB13), an immunogenic variant thereof, or an immunogenic fragment of the HOXB13 or the immunogenic variant thereof; and (v) an amino acid sequence comprising NK3 Homeobox 1 (NKX3-1), an immunogenic variant thereof, or an immunogenic fragment of the NKX3-1 or the immunogenic variant thereof.
-
公开(公告)号：US20210277133A1
公开(公告)日：2021-09-09
申请号：US17172700
申请日：2021-02-10
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
Patent Agency Ranking
公开(公告)号：US20210269541A1
公开(公告)日：2021-09-02
申请号：US17172698
申请日：2021-02-10
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
公开(公告)号：US20240327544A1
公开(公告)日：2024-10-03
申请号：US18579086
申请日：2022-07-13
Applicant: BIONTECH SE , GENMAB A/S
Inventor： Ugur SAHIN , Alexander MUIK , Sina FELLERMEIER-KOPF , Yali FU , Homer ADAMS, III , Gaurav BAJAJ , Brandon HIGGS , Mark FERESHTEH , Vanessa SPIRES , Jordan BLUM , Patricia GARRIDO CASTRO , Michelle NIEWOOD , Friederike GIESEKE , Karsten BECKMANN , Claudia PAULMANN , Ivan KUZMANOV , Esther Cornelia Wilhelmina BREIJ , Lars GUELEN , Jost NEIJSSEN , Bart-Jan DE KREUK , Richard HIBBERT , Janine SCHUURMAN , Aran Frank LABRIJN
CPC classification number: C07K16/468 , A61K2039/505 , C07K2317/31 , C07K2317/33 , C07K2317/52 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/76
Abstract: The present invention relates to combination therapy using a binding agent that binds to human CD40 and to human CD137 in combination with a checkpoint inhibitor to reduce or prevent progression of a tumor or treating cancer.
-
8.发明公开公开(公告)号：US20230365693A1
公开(公告)日：2023-11-16
申请号：US18315686
申请日：2023-05-11
Applicant: BioNTech SE , Genmab A/S
Inventor： Ugur SAHIN , Sina FELLERMEIER-KOPF , Friederike GIESEKE , Karsten BECKMANN , Claudia PAULMANN , Alexander MUIK , Ivan KUZMANOV , Esther Cornelia Wilhelmina BREIJ , Patricia GARRIDO CASTRO , Jordan BLUM , Lars GUELEN , Joost NEIJSSEN , Bart-Jan DE KREUK , Richard HIBBERT , Janine SCHUURMAN , Aran Frank LABRIJN
IPC: C07K16/28
CPC classification number: C07K16/2818 , C07K2317/24 , C07K2317/92
Abstract: The present disclosure relates to antibodies having the ability to bind to the immune checkpoint protein programmed death-1 (PD-1), such as human PD-1, or nucleic acids encoding such antibodies, wherein the antibodies comprise modifications in the Fc region eliminating or reducing a Fc-mediated effector function of the antibodies. The present disclosure also relates to compositions or kits comprising said antibodies or nucleic acids, as well as to the use of these antibodies or nucleic acids or compositions in the field of medicine, preferably in the field of immunotherapy, e.g., for the treatment of cancers. The present invention further relates to methods for inducing an immune response in a subject comprising providing to the subject an antibody of the present disclosure or one or more nucleic acids encoding such an antibody, or a composition comprising said antibody or nucleic acids.
-
公开(公告)号：US20220378910A1
公开(公告)日：2022-12-01
申请号：US17854649
申请日：2022-06-30
Applicant: Genentech, Inc. , BioNTech SE , Hoffmann-La Roche Inc.
Inventor： Lars MUELLER , Rachel Lubong SABADO , Mahesh YADAV , Jingbin ZHANG , Ugur SAHIN
Abstract: The present disclosure provides methods for inducing neoepitope-specific CD8+ T cells in an individual or for inducing trafficking of neoepitope-specific CD8+ T cells to a tumor in an individual using an RNA vaccine or using an RNA vaccine in combination with a PD-1 axis binding antagonist. Also provided herein are PD-1 axis binding antagonists and RNA vaccines that include one or more polynucleotides encoding one or more neoepitopes resulting from cancer-specific somatic mutations present in a tumor specimen obtained from the individual for use in methods of inducing neoepitope-specific CD8+ T cells in an individual or for inducing trafficking of neoepitope-specific CD8+ T cells to a tumor in an individual.
-
公开(公告)号：US20200165349A1
公开(公告)日：2020-05-28
申请号：US16779011
申请日：2020-01-31
Applicant: GENMAB A/S , BIONTECH SE
Inventor： Isil ALTINTAS , David SATIJN , Rik RADEMAKER , Paul PARREN , Ugur SAHIN , Friederike GIESEKE , Alexander MUIK , Christian GRUNWITZ
IPC: C07K16/28
Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
-
-
-
-
-
-
-
-
-
Search Results
33
records
(took 0.02 seconds)
